Most of the recent pump was so that BTX could dilute & borrow/dilute another $100 million worth. Check the filings for an S3 around January.
As usual, retail cannon fodder got successfully sucked in.
And, as usual, all the "longs" here shut up as soon as they got out, leaving a new class of newbies to drop out or become cult members.
"They do certainly need to do a little more PR at least" Uh...what else besides PR DO they do??
Oh....get welfare checks to retiring out fellow travelers in the corspsicle cult.... and sell T-shares.
BTX does appear to be working hard toi get another couple of generics onto the mkt, which may, after 20 years, bring in revs almost equal to the cost of development.
"The retail investor has very little to do with this company. " False. Retail road kill is the raw material for one of BTX's two successful products: Hextend and T-shares.
Retail cannon fodder is what keeps the price above 14X sales--- thereby keeping this dog listed .
Those BTX "products" are attempts at "me too" generics. Like everything else BTX has ever brought to mkt.
"Nearing the end of cash on hand." Probably not. Check the change in O/S. As long as gameboys like the "longs" here can keep sucking in retail cannon fodder, BTX will keep diluting its way into being" ongoing."
BTX S-1 was 3mm (split adjusted to 9) It's now looking at 60mm--possibly in the rear view mirror.
Two thirds of that has happened since the D/E swap that moved Mikey from the BOD to CEO.
Which one? The one proven to work. So PanC generic equivalent willo retail at $500? wHen did Mikey promise that? If it is the price, how much goes to BTX?
Talk is not cheap: it's 90% of BTX's mkt cap.
Great job of showing what a liar you are. Nobody said a word about RS. And BTX can (as it likely will have to,) print another couple hundred million shares before he idea makes any sense at all.
THat's not how AK and Mikey play the game. Notice how once their options were locked in, the price doubled....especially under the pressure of generating the smoke&mirrors to do $100 in T-stock, bonds, etc. SEe the s-3 from around January.
To do TA on this dog, reading the filings is essential. .. Then it can be traded into accumulation, or just rolled, long or short, or long AND short---which is now obviously the case for some of the "longs" here.
Good job of restarting the pump'n'dump for you and other cronies. Except that the bottom is no where in on this dog--if anyone actually reads the 10-Q.
At what price? The cronies and game boys around here have bases at zero or below . They got that way by trading into accumulation.
To do that successfully, they use "buy&hold" guys like you as cannon fodder.
Because they get retail road kill to get shares for free. Take a look at where Mikey had his far out options priced last year....
Google could easily buy all of the BTX i/p at 20% over what BTX prices it for.... which would put this dog trading back under 6 bits.
Read the filings, not the press releases.
Utill the lats round of pump&dump dilution vol was around 120K--and2nd 2 years before that vol was~60k.
Learn to read a 5 year chart. and the filings.
"by year end this company is bankrup" NOpe. not at all.
"there will so much stock outstanding that it will be difficult to ever show any real PE ratio." Already is.
Mikey's last enterprise went from around 12 million shares to over a billion before caving in.
which means look for BTX's next round of dilution.
It's part of the old school boiler room tactics that BTX used from '96 to 2008 to start a witch hunt for "evil shorts."
Anyone notice ho9w much the sohrt interest went down after this dog went back under 3?
" who does technical analysis? If so, please give me your conclusions." Sure---earnings come from doing, and welfare queens like you and BTX try to get around that. That's what the T/A says.
Take a hard look at how BTX itself values those patents. If this dog traded at the "future value of its i/p" the tape would float around 2 bits. And that's according to BTX itself.
Most of those patents are or obsolete ways of doing stuff that doesn't meet any medical reality. Many of the rest are about making generics that will sell for below "name brand" existing products. A few are about what could be very useful products . Those however are unlikely to earn back their R&D and regulatory costs.
You've been here for around 7 years, saying he same thing over and over: Next year BTX will be at double digits. ANd you have never once been right.
Sure it is.... Those "long" boiler room guys are responsible to the insiders and cronies that feed on retail road kill.